Smart + Strong.
All Rights Reserved.
Smart + Strong®
is a registered trademark of CDM Publishing, LLC.
Given every four weeks, the combo injection of cabotegravir and Edurant (rilpivirine) will likely face an FDA decision by early 2020.
An early trial of Gilead’s HIV capsid inhibitor supports three-month dosing.
The trial will investigate whether injections of long-acting cabotegravir and rilpivirine yield a superior rate of viral suppression.
Dosed every four weeks, the injection, which requires a clinic visit, includes long-acting rilpivirine and cabotegravir.
A series of antibody infusions suppressed HIV for up to four months without prompting the virus to develop resistance.
The Conference on Retroviruses and Opportunistic Infections in Seattle saw many important studies that are advancing the fight against HIV.
Participants in a study were started on daily oral drugs and then half were switched over to long-acting meds.
The antiretroviral GS-6207 is injected under the skin and would need to be combined with other meds to fully suppress HIV.
Researchers have devised a means of injecting an antiretroviral under the skin that hardens into a dissolvable and removable implant.
Periodic infusions of long-acting HIV antibodies may eventually become a new way of treating the virus.
Promising findings from a study of a two-drug injectable treatment given every four weeks.
The company has released new data from a trial of injectable cabotegravir and Edurant given every four or eight weeks.
Researchers polled people on HIV treatment about their preferences for various forms of long-acting antiretrovirals.
Periodic infusions of such antibodies may eventually become a new way of treating the virus.
You have been inactive for 60 minutes and will be logged out in . Any updates not saved will be lost.
Click here to log back in.